Press Releases

The Assistance Fund Opens New Program for Hereditary (ATTR) Amyloidosis


The Assistance Fund Launches New Program to Provide Financial Support to Individuals with Hereditary (ATTR) Amyloidosis  

ORLANDO, Fla., August 20, 2018 — The Assistance Fund, an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs, launched a new financial assistance program to provide support for individuals with Hereditary (ATTR) Amyloidosis. The program covers out-of-pocket medical expenses, including medication copays, health insurance premiums, deductibles, coinsurance and incidental medical expenses for eligible individuals.

“It is with great excitement that we open this new financial assistance program so that patients with Hereditary (ATTR) Amyloidosis can pursue treatment without being burdened by undue financial stress,” said The Assistance Fund President and CEO Mark P. McGreevy.

“Hereditary Amyloidosis has a huge impact on families, in which generations may be affected by the disease,” said Isabelle Lousada, President and CEO of the Amyloidosis Research Consortium. “As the disease progresses, patients experience a considerable impact on their quality of life and ability to work, as well as their social and emotional well-being. New treatments that can slow progression and minimize the effect of symptoms offer real hope to patients.”

Hereditary (ATTR) Amyloidosis is a condition that affects organ tissue structure and function when amyloid, an abnormal protein, is deposited in multiple organs where it should not be, most often in tissues of the heart, kidneys and nervous system.1 Symptoms can vary broadly among patients and may include heart palpitations and abnormal heart rhythms, a loss of sensation in the extremities, digestive issues, swelling, and many other issues.2

“Finally, patients have hope for treating this disease,” said Mary O’Donnell, President and CEO of the Amyloidosis Foundation. “The Assistance Fund’s financial assistance program for Hereditary (ATTR) Amyloidosis will provide extremely important support for patients who may otherwise be unable to seek treatment due to high out-of-pocket costs.”

To learn more or determine eligibility for financial support from The Assistance Fund, individuals should visit or call 855-512-2801 to speak with a patient advocate.

A list of all the programs available at The Assistance Fund can be found on the website

About The Assistance Fund

The Assistance Fund is an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs by providing financial assistance for their copayments, coinsurance, deductibles and other health-related expenses. The Assistance Fund currently manages more than 40 programs – each of which covers the FDA-approved medications that treat a specific disease. Since its founding in 2009, The Assistance Fund has helped more than 73,000 adults and children access the medicines they need to stay healthy or manage a chronic condition. To learn more about The Assistance Fund, or for information on how to donate, please visit

Media Contact

Margaret Figley

Director of Communications References 1- “Hereditary amyloidosis” National Institutes of Health, National Center for Advancing Translational Sciences, Genetic and Rare Diseases Information Center. Retrieved from: 2-“Hereditary amyloidosis.” Amyloidosis Foundation. Retrieved from:

Share This
Categories: Press Releases